{"id":"NCT00668525","sponsor":"Forest Laboratories","briefTitle":"Escitalopram in Adult Patients With Major Depressive Disorder","officialTitle":"A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-02","completion":null,"firstPosted":"2008-04-29","resultsPosted":"2010-05-06","lastUpdate":"2010-05-11"},"enrollment":877,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Escitalopram","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Escitalopram","otherNames":[]}],"arms":[{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"EXPERIMENTAL"},{"label":"1","type":"PLACEBO_COMPARATOR"}],"summary":"This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.","primaryOutcome":{"measure":"Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.","timeFrame":"Change from baseline in MADRS total score at week 8","effectByArm":[{"arm":"Escitalopram Low Dose","deltaMin":-12.8,"sd":0.6},{"arm":"Escitalopram High Dose","deltaMin":-13.4,"sd":0.6},{"arm":"Placebo","deltaMin":-10.1,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":322},"commonTop":["Headache","Nausea","Diarrhea","Insomnia","Dry mouth"]}}